In a landmark development for mental health treatment, the United States Food and Drug Administration (US FDA) has approved the first at-home medical device designed to help manage symptoms of depression. The approval represents a major milestone in digital therapeutics and neuromodulation, offering patients a
Investment in Belgium’s Frid Mind Technologies to Advance Stroke Prevention Acquisition of Stake in Israel’s Motion Informatics to Strengthen Stroke Rehabilitation Portfolio Development of advanced Braided Devices for Neurovascular and Peripheral Vascular CareBiorad Medisys Pvt. Ltd. today outlined a series of product development
Medtronic, a global leader in healthcare technology, today announced the launch of its next-generation electrosurgical energy platform in India — the Valleylab™ FT10 series. The new portfolio includes the Valleylab™ FT10 Electrosurgical Generator (VLFT10FXGEN) and the Valleylab™ FT10 Vessel Sealing Generator (VLFT10LSGEN), both of which
Healthium Medtech, a global player in medical devices, focused on products in surgical and post-surgical ecosystem including wound closure, advanced wound care, arthroscopy and infection prevention segments, has announced the appointment of Rajnish Damani as Group Chief Operating Officer (COO). In this newly created leadership
JATIN MAHAJANSecretary, Association of Diagnostics Manufacturers of India (ADMI)The perception that imported products are superior to Indian-made ones is deeply ingrained in the Indian psyche, rooted more in legacy and sentiment than in objective reality. However, this perception is increasingly outdated. India has made significant
Sahajanand Medical Technologies (SMT), a global leader in cardiovascular device innovation, is pleased to announce the appointment of two new members to its Board of Directors: Harvinder Pal Singh, who will serve as Independent Director, and Priyanka Dhirajlal Cohen, who joins as Non-Executive Director.Harvinder Pal
Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended December 31, 2024. Financial Summary (All numbers in INR Mn., except Margins) QUARTERLY CONSOLIDATED FINANCIALS Q3FY25 Q2FY25 Growth (QoQ) Q3FY24 Growth (YoY)Revenue from Operations 11,377 9,666 18% 11,556 -2%EBITDA 2,303 2,033 13% 2,505 -8%EBITDA % 20% 21% 22% PAT 1,176 972 21% 1,257 -6%PAT % 10% 10% 11% Financial and Business Summary for Q3FY25The Company voluntarily paused
Government of India has formulated a scheme namely “Promotion of Research and Innovation in Pharma MedTech Sector”The industry, academia and policy makers need to work together to create a future-ready workforcePolicymakers and Industry Experts advocate closer collaboration and partnerships between Industry and Academia in MedTech SectorVisit of G-20 delegates at
In order to make quality drugs affordable and accessible to all Indian patients, Mankind Pharma which [manufactures] [NEPTAZ using US FDA approved DMF grade API] has announced a price reduction of up to 70% across different SKUs for its brand NEPTAZ (Sacubitril/Valsartan). This price reduction
